Artwork

Inhoud geleverd door www.MaximSherstobitov.NZ. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door www.MaximSherstobitov.NZ of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !

AFT Pharmaceuticals (NZX-AFT) Stock Review & Growth Trends

33:58
 
Delen
 

Manage episode 327622241 series 3116466
Inhoud geleverd door www.MaximSherstobitov.NZ. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door www.MaximSherstobitov.NZ of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

AFT reported a strong lift in revenue and earnings following sales growth and cost control in its diversified Australasian medicines business and growing sales of its Maxigesic drug.
This talk is presented by Hartley Atkinson - CEO - AFT Pharmaceuticals Ltd.

Revenue for the year to 31 March 2020 increased 24% to $105.6 million from $85.1 million in the prior financial year, with revenue growing strongly in Australia (up 22%), New Zealand (up 12%) and Asia (up 130%). The international business, which is focused primarily on the commercialisation of Maxigesic was up 55%.
Operating profit rose to $21.1 million, building on last year's $6.1 million operating profit by $15.0 million. The result included a non-cash $9.8 million non-recurring gain related to AFT taking full control of the Pascomer dermatological medicine2 intellectual property.
Excluding the one-off gain, the underlying operating profit of $11.4 million represented an 86% improvement on the prior year's result and reflects continued sales growth, the return to more normalised research and development spending and careful management of costs throughout the business.

Net profit after tax rose to $12.7 million from a loss of $2.4 million in the same period a year ago, demonstrating the operating leverage present in our business
AFT Pharmaceuticals Chairman David Flacks said: "The Board is delighted to report on an outstanding year. For the first time we broke through $100 million sales and delivered record earnings.
"Momentum has continued to build across our business in the last financial year. Our Australasian business continues to grow strongly extending a two-decade record of growth."
Learn other tips at https://www.MaximSherstobitov.NZ/

Subscribe on YouTube now so you do not miss the next video ➜ https://www.youtube.com/channel/UCHIw-Ej9kivd77bavBCnatQ?sub_confirmation=1

➔ Facebook Page - https://www.facebook.com/MaximSherstobitovPage/

➔ Instagram - https://www.instagram.com/maxim.sherstobitov/

➔ LinkedIn - https://www.linkedin.com/in/maximsherstobitov/

➔ Subscribe to the Podcast

➔ Join my exclusive weekly newsletter http://eepurl.com/gcmTU9
IMPORTANT:
- The information does not constitute financial, accounting or legal advice and we cannot be held liable for any acts or omissions that arise from your use.
- Everything on this channel is for educational purposes only. It does not take into account your investment objectives, financial situation and personal needs.
- Past performance is not a guarantee of future returns. Before making any financial decisions, you should seek independent financial advice.

  continue reading

36 afleveringen

Artwork
iconDelen
 
Manage episode 327622241 series 3116466
Inhoud geleverd door www.MaximSherstobitov.NZ. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door www.MaximSherstobitov.NZ of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

AFT reported a strong lift in revenue and earnings following sales growth and cost control in its diversified Australasian medicines business and growing sales of its Maxigesic drug.
This talk is presented by Hartley Atkinson - CEO - AFT Pharmaceuticals Ltd.

Revenue for the year to 31 March 2020 increased 24% to $105.6 million from $85.1 million in the prior financial year, with revenue growing strongly in Australia (up 22%), New Zealand (up 12%) and Asia (up 130%). The international business, which is focused primarily on the commercialisation of Maxigesic was up 55%.
Operating profit rose to $21.1 million, building on last year's $6.1 million operating profit by $15.0 million. The result included a non-cash $9.8 million non-recurring gain related to AFT taking full control of the Pascomer dermatological medicine2 intellectual property.
Excluding the one-off gain, the underlying operating profit of $11.4 million represented an 86% improvement on the prior year's result and reflects continued sales growth, the return to more normalised research and development spending and careful management of costs throughout the business.

Net profit after tax rose to $12.7 million from a loss of $2.4 million in the same period a year ago, demonstrating the operating leverage present in our business
AFT Pharmaceuticals Chairman David Flacks said: "The Board is delighted to report on an outstanding year. For the first time we broke through $100 million sales and delivered record earnings.
"Momentum has continued to build across our business in the last financial year. Our Australasian business continues to grow strongly extending a two-decade record of growth."
Learn other tips at https://www.MaximSherstobitov.NZ/

Subscribe on YouTube now so you do not miss the next video ➜ https://www.youtube.com/channel/UCHIw-Ej9kivd77bavBCnatQ?sub_confirmation=1

➔ Facebook Page - https://www.facebook.com/MaximSherstobitovPage/

➔ Instagram - https://www.instagram.com/maxim.sherstobitov/

➔ LinkedIn - https://www.linkedin.com/in/maximsherstobitov/

➔ Subscribe to the Podcast

➔ Join my exclusive weekly newsletter http://eepurl.com/gcmTU9
IMPORTANT:
- The information does not constitute financial, accounting or legal advice and we cannot be held liable for any acts or omissions that arise from your use.
- Everything on this channel is for educational purposes only. It does not take into account your investment objectives, financial situation and personal needs.
- Past performance is not a guarantee of future returns. Before making any financial decisions, you should seek independent financial advice.

  continue reading

36 afleveringen

Усі епізоди

×
 
Loading …

Welkom op Player FM!

Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.

 

Korte handleiding